A Phase 2 interventional study of Selinexor and Placebo in Coronavirus Infection, sponsored by Karyopharm Therapeutics Inc. Completed at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-20.
Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 498th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 154th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo. The study had 2 arms and evaluated selinexor 20 mg + standard of care (SoC) and placebo + SoC. As the treatment for COVID-19 is rapidly evolving, the SoC varied over time and across regions of the world.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 190 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has symptoms of severe COVID-19 as demonstrated by:
Exclusion Criteria:
Evidence of critical COVID-19 based on:
Inadequate hematologic parameters as indicated by the following labs:
Inadequate renal and liver function as indicated by the following labs:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
Drug: Selinexor
Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
Other: Placebo
Participants will receive 20 mg of selinexor.
Also known as: KPT-330, XPOVIO
Participants will receive 20 mg of placebo matched to selinexor.
Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale
Ordinal Scale 2-Point improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
Time frame: Baseline up to Day 14
Percentage of Participants With at Least a 2-Point Improvement in the Ordinal Scale up to Day 7
Ordinal Scale 2-points improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 7. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where, 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
Time frame: Baseline up to Day 7
Percentage of Participants With at Least a 1-Point Improvement in the Ordinal Scale
Ordinal Scale 1-point improvement was defined as percentage of participants with at least 1-point improvement (increase from baseline) by Day 7 and 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
Time frame: Baseline up to Day 7 and 14
Time to Clinical Improvement of 2-points Using Ordinal Scale (TTCI-2)
TTCI-2 was defined as the time from randomization to an improvement of 2-points using 8-points Ordinal Scale. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
Time frame: Baseline up to Day 28
Overall Death Rate
Overall death rate was defined as the percentage of participants who died on or before Day 28.
Time frame: Baseline up to Day 28
Rate of Mechanical Ventilation (RMV)
The rate of RMV was defined as the percentage of participants who ever used invasive mechanical ventilation or ECMO during the hospital stay.
Time frame: Baseline up to Day 28
Rate of Intensive Care Unit (ICU) Admission
The rate of ICU admission was defined as the percentage of participants with ICU admissions.
Time frame: Baseline up to Day 28
Length of Hospitalization
Length of hospitalization (days) was defined as (first hospital discharge date - date of randomization + 1).
Time frame: Baseline up to Day 67
Change From Baseline in C-reactive Protein (CRP) Levels
The anti-inflammatory and immune effects of selinexor were assessed by CRP levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26
Change From Baseline in Ferritin Levels
The anti-inflammatory and immune effects of selinexor were assessed by ferritin levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26
Change From Baseline in Lactate Dehydrogenase (LDH) Levels
The anti-inflammatory and immune effects of selinexor were assessed by LDH levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline, Day 3, 5, 8, 12, 15, 19, 22 and 26
Changes From Baseline in Blood Plasma Cytokines Levels-Interleukin-6 (IL-6)
The anti-inflammatory and immune effects of selinexor were assessed by blood plasma cytokines like IL-6. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
Time frame: Baseline, Day 3, 5, 8, 12, 15, 22 and 26
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
Adverse events are defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both Serious and non-serious TEAEs.
Time frame: From start of study drug administration up to Day 58
This study was conducted at 20 sites in the United States of America,1 site in Austria, 3 sites in France and Israel, 2 sites in Spain, and 4 sites in the United Kingdom from 17 Apr 2020 to 05 Oct 2020.
| Milestone | Selinexor 20 mg | Placebo |
|---|---|---|
| Started | 103 | 87 |
| Treated | 102 | 86 |
| Completed | 65 | 61 |
| Not completed | 38 | 26 |
| Withdrew: Death | 16 | 8 |
| Withdrew: Lost to follow-up | 11 | 8 |
| Withdrew: Withdrawal by subject | 8 | 5 |
| Withdrew: Other | 3 | 5 |
Ordinal Scale 2-Point improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
| Percentage of participants | Selinexor 20 mg | Placebo |
|---|---|---|
| Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale | 60.6 (47.8 to 72.4) | 60.8 (46.1 to 74.2) |
Ordinal Scale 2-points improvement was defined as percentage of participants with at least a 2-points improvement (increase from baseline) by Day 7. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where, 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
| Percentage of participants | Selinexor 20 mg | Placebo |
|---|---|---|
| Percentage of Participants With at Least a 2-Point Improvement in the Ordinal Scale up to Day 7 | 30.1 (21.5 to 39.9) | 32.2 (22.6 to 43.1) |
Ordinal Scale 1-point improvement was defined as percentage of participants with at least 1-point improvement (increase from baseline) by Day 7 and 14. Baseline score was defined as the last score measured before first dosing. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or ECMO; 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
| Percentage of participants | Selinexor 20 mg | Placebo |
|---|---|---|
| Day 7 | 51.5 (41.4 to 61.4) | 50.6 (39.6 to 61.5) |
| Day 14 | 72.8 (63.2 to 81.1) | 72.4 (61.8 to 81.5) |
TTCI-2 was defined as the time from randomization to an improvement of 2-points using 8-points Ordinal Scale. The 8-point ordinal scale ranges from 1 to 8: where 1= death, 2= hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5= hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus disease 2019 \[COVID-19\] related or otherwise); 6= hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7= not hospitalized, limitation on activities and/or requiring home oxygen; 8= not hospitalized, no limitations on activities.
| Days | Selinexor 20 mg | Placebo |
|---|---|---|
| Time to Clinical Improvement of 2-points Using Ordinal Scale (TTCI-2) | 10.0 (8.0 to 14.0) | 10.0 (8.0 to 14.0) |
Overall death rate was defined as the percentage of participants who died on or before Day 28.
| Percentage of participants | Selinexor 20 mg | Placebo |
|---|---|---|
| Overall Death Rate | 15.2 (7.5 to 26.1) | 3.9 (0.5 to 13.5) |
The rate of RMV was defined as the percentage of participants who ever used invasive mechanical ventilation or ECMO during the hospital stay.
| Percentage of participants | Selinexor 20 mg | Placebo |
|---|---|---|
| Rate of Mechanical Ventilation (RMV) | 13.6 (6.4 to 24.3) | 11.8 (4.4 to 23.9) |
The rate of ICU admission was defined as the percentage of participants with ICU admissions.
| Percentage of participants | Selinexor 20 mg | Placebo |
|---|---|---|
| Rate of Intensive Care Unit (ICU) Admission | 48.5 (36.0 to 61.1) | 41.2 (27.6 to 55.8) |
Length of hospitalization (days) was defined as (first hospital discharge date - date of randomization + 1).
| Days | Selinexor 20 mg | Placebo |
|---|---|---|
| Length of Hospitalization | 9.0 (3 to 39) | 9.0 (3 to 67) |
The anti-inflammatory and immune effects of selinexor were assessed by CRP levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
| milligram per liter (mg/L) | Selinexor 20 mg | Placebo |
|---|---|---|
| Change at Day 3 | -47.9660 ± 99.06082 | -42.9658 ± 89.09341 |
| Change at Day 5 | -74.4735 ± 114.52388 | -68.6191 ± 108.19671 |
| Change at Day 8 | -83.3460 ± 93.83500 | -74.4669 ± 117.66505 |
| Change at Day 12 | -86.9158 ± 123.54705 | -93.2744 ± 131.56709 |
| Change at Day 15 | -87.9800 ± 121.19999 | -98.7940 ± 87.65276 |
| Change at Day 19 | -66.2143 ± 86.55049 | -124.3233 ± 102.04161 |
| Change at Day 22 | -90.7100 ± 149.25579 | -47.5620 ± 171.49171 |
| Change at Day 26 | -37.2800 ± 141.41390 | -129.5020 ± 46.26178 |
The anti-inflammatory and immune effects of selinexor were assessed by ferritin levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
| microgram/liter (mcg/L) | Selinexor 20 mg | Placebo |
|---|---|---|
| Change at Day 3 | 80.8415 ± 759.10075 | -61.9843 ± 542.09460 |
| Change at Day 5 | -25.7000 ± 856.16619 | -155.3111 ± 773.76777 |
| Change at Day 8 | 226.6113 ± 1673.46162 | -292.2462 ± 738.07874 |
| Change at Day 12 | 193.5793 ± 1203.33385 | -352.5280 ± 741.13673 |
| Change at Day 15 | 204.3900 ± 557.29217 | -356.8429 ± 476.04151 |
| Change at Day 19 | -15.9333 ± 462.40358 | -231.2374 ± 599.98919 |
| Change at Day 22 | -103.9900 ± 636.89555 | -102.0000 ± 417.51247 |
| Change at Day 26 | -150.1167 ± 535.94141 | -25.7500 ± 231.43232 |
The anti-inflammatory and immune effects of selinexor were assessed by LDH levels. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
| units/liter (U/L) | Selinexor 20 mg | Placebo |
|---|---|---|
| Change at Day 3 | -13.86 ± 148.231 | -11.86 ± 151.630 |
| Change at Day 5 | -49.12 ± 175.722 | 31.85 ± 326.281 |
| Change at Day 8 | -75.85 ± 264.840 | -10.93 ± 166.876 |
| Change at Day 12 | -107.39 ± 198.092 | -16.84 ± 232.605 |
| Change at Day 15 | -71.82 ± 193.543 | -51.50 ± 148.063 |
| Change at Day 19 | -96.38 ± 200.164 | -74.14 ± 114.271 |
| Change at Day 22 | -129.70 ± 177.454 | -75.40 ± 43.569 |
| Change at Day 26 | -169.50 ± 213.481 | 4.50 ± 130.733 |
The anti-inflammatory and immune effects of selinexor were assessed by blood plasma cytokines like IL-6. Baseline was defined as the most recent non-missing measurement prior to the first administration of study treatment. Change from Baseline at the indicated time points was calculated as the value at the indicated time points minus the value at Baseline.
| nanograms/milliliter (ng/mL) | Selinexor 20 mg | Placebo |
|---|---|---|
| Change at Day 3 | -19.931 ± 51.2072 | 2.046 ± 49.0258 |
| Change at Day 5 | -10.786 ± 102.9160 | -77.509 ± 408.0085 |
| Change at Day 8 | -13.909 ± 161.6803 | 183.728 ± 662.7908 |
| Change at Day 12 | 276.289 ± 1541.3692 | 223.637 ± 715.5904 |
| Change at Day 15 | -34.850 ± 28.6357 | 207.625 ± 408.5783 |
| Change at Day 22 | -8.600 ± 11.8072 | — |
| Change at Day 26 | -23.400 | — |
Adverse events are defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both Serious and non-serious TEAEs.
| Participants | Selinexor 20 mg | Placebo |
|---|---|---|
| Participants with TEAEs | 75 | 49 |
| Participants with Serious TEAEs | 23 | 14 |
Collected over From start of study drug administration up to Day 58. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selinexor 20 mg | 16/102 (15.7%) | 23/102 (22.5%) | 69/102 (67.6%) |
| Placebo | 8/86 (9.3%) | 14/86 (16.3%) | 45/86 (52.3%) |
| Event | Selinexor 20 mg | Placebo |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 6/102 | 2/86 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/102 | 2/86 |
| Myocardial infarctionCardiac disorders | 0/102 | 2/86 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/102 | 2/86 |
| COVID-19Infections and infestations | 0/102 | 2/86 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/102 | 2/86 |
| Cardiac arrestCardiac disorders | 2/102 | 0/86 |
| Acute kidney injuryRenal and urinary disorders | 2/102 | 1/86 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/102 | 0/86 |
| Atrial fibrillationCardiac disorders | 1/102 | 1/86 |
| Event | Selinexor 20 mg | Placebo |
|---|---|---|
| HyponatraemiaMetabolism and nutrition disorders | 24/102 | 5/86 |
| ConstipationGastrointestinal disorders | 14/102 | 9/86 |
| NauseaGastrointestinal disorders | 13/102 | 6/86 |
| DiarrhoeaGastrointestinal disorders | 10/102 | 4/86 |
| AnaemiaBlood and lymphatic system disorders | 9/102 | 1/86 |
| Aspartate aminotransferase increasedInvestigations | 9/102 | 7/86 |
| Alanine aminotransferase increasedInvestigations | 8/102 | 4/86 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/102 | 3/86 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 6/102 | 2/86 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 4/102 | 5/86 |
PV 1-6 population included participants randomized into the study under protocol versions 1-6.
| Age, Continuous(Years) | Selinexor 20 mg | Placebo | Total |
|---|---|---|---|
| Mean | 56.5 ± 16.12 | 56.5 ± 14.64 | 56.5 ± 15.42 |
| Sex: Female, Male(Participants) | Selinexor 20 mg | Placebo | Total |
|---|---|---|---|
| Female | 43 | 39 | 82 |
| Male | 60 | 48 | 108 |
| Ethnicity (NIH/OMB)(Participants) | Selinexor 20 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 41 | 32 | 73 |
| Not Hispanic or Latino | 59 | 53 | 112 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Selinexor 20 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 23 | 24 | 47 |
| White | 44 | 34 | 78 |
| More than one race | 19 | 14 | 33 |
| Unknown or Not Reported | 9 | 11 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2020 to primary completion in Oct 2020, 5 months.
Results were first posted in Nov 2021, 1 year after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 5 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor